The Zacks Analyst Blog Highlights: Chevron, Novartis, Qualcomm, TJX And Deere
Zacks Investment Research | Nov 15, 2018 07:38AM ET
For Immediate Release
Chicago, IL –November 15, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Chevron (NYSE:CVX) , Novartis (NYSE:NVS) , Qualcomm (NASDAQ:QCOM) , TJX (NYSE:TJX) and Deere (NYSE:DE) .
Here are highlights from Wednesday’s Analyst Blog:
Top Analyst Reports for Chevron, Novartis and Qualcomm
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Chevron, Novartis and Qualcomm. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.
Chevron’s shares have declined 7.9% so far this year, underperforming the Zacks Integrated Oil industry's 5.8% decrease. However, Chevron's Q3 earnings more than doubled year over year and was ahead of analysts' expectations. Cash flow was at its highest level in nearly 5 years, while upstream production hit a record.
Chevron’s existing oil and gas development project pipeline is among the best in the industry, targeting volume growth of around 7% in 2018 thanks to planned expansion in the Permian Basin. The oil supermajor pumped 80% more out of the West Texas shale play in the quarter compared with the same period last year, with production set to soar in coming years.
Moreover, the enormous increase in cash flow enabled Chevron to repurchase $750 million of its own shares. Yet there are worries over a drop in its downstream earnings due to weak international margins that once again cut into overall gains from rising E&P income. Hence, investors are advised to wait for a better entry point before buying shares of Chevron.
Shares of Novartis have outperformed the Zacks Large-Cap Pharmaceuticals industry (+14% vs. +12%), in the last six months. Novartis beat sales estimates in the third quarter on strong performance of Cosentyx and Entresto. The label expansion of oncology drugs also boost the top line.
Novartis has a strong oncology portfolio including drugs like Afinitor, Exjade, Jakavi, Zykadia, Tasigna, Jadenu and Kisqali, which continue to boost sales. Novartis restructured its business and plans to focus on becoming a core drug-focused company, powered by data and digital technologies. The company is looking to solidify its presence in the gene-therapy space. It acquired U.S.-based clinical stage gene therapy company, AveXis, Inc.
Novartis also announced that it will acquire Endocyte to further strengthen its pipeline. However, generic division Sandoz continues to face pricing pressure. The division also suffered a blow when the FDA issued a CRL to its generic Advair Diskus.
Qualcomm’s shares have lost 17.5% over the past year vs +6% for the Zacks Wireless Equipment industry. Regulatory disputes and aggressive competition in the mobile phone chipset market will likely hurt Qualcomm in future. However, Qualcomm reported healthy fourth-quarter fiscal 2018 results backed by proper execution of its strategic priorities to drive technology and product leadership.
The company has been trying to retain its leadership in 5G, chipset market and mobile connectivity with multiple technological achievements and innovative product launches. It expects growth from its China business in fiscal 2019, particularly in the second half.
While Qualcomm expanded its leadership to the high tiers with Snapdragon 700, its Snapdragon 800 solutions will continue defining the premium tier benchmarks. The product mix is improving in the China region and key Qualcomm China-based customers are gaining share globally, auguring well for its future business growth.
Other noteworthy reports we are featuring today include TJX and Deere.
3 Medical Stocks to Buy Now
The greatest discovery in this century of biology is now at the flashpoint between theory and realization. Billions of dollars in research have poured into it. Companies are already generating revenue, and cures for a variety of deadly diseases are in the pipeline.
So are big potential profits for early investors. Zacks has released an updated Special Report that explains this breakthrough and names the best 3 stocks to ride it.
Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.